Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.
Amgen has hit back at Sandoz’ petition for a writ of certiorari against a US Court of Appeals for the Federal Circuit decision that leaves the biosimilar sponsor unable to market its Enbrel biosimilar more than three decades after the biologic was first launched.
Canada’s PlantForm has struck a deal with Brazil’s Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab rival to Merck’s Keytruda for the Brazilian market and potentially beyond.
Centus Biotherapeutics and Roche’s Genentech have agreed to settle US patent litigation over the biosimilars firm’s FKB238 proposed bevacizumab rival to Avastin.
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.
Biosimilars industry stakeholders have suggested ways to enhance communication and improve the US regulatory pathway for biosimilars, as they weighed in on an interim assessment of the program for enhanced review transparency and communication in the Biosimilar User Fee Act II, ahead of the upcoming reauthorization of BsUFA for fiscal years 2023 through 2027 by the FDA.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.